Bladder tumour
Conditions
Interventions
Sugammadex group (S group):After surgery, administer sugammadex 2 mg/kg intravenously when the third twitch (T3) appears during the train-of-four (TOF) stimulation, and remove the laryngeal mask when
Neostigmine group (N group):After surgery, administer neostigmine 0.05 mg/kg intravenously (maximum dose 5 mg) + atropine 0.02 mg/kg when the third twitch (T3) appears during the train-of-four (TOF) s
Sponsors
Anqing Municipal Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective transurethral resection of bladder tumor; 2. ASA classification I-III; 3. Age 60-80 years; 4. BMI 18-32 kg/m^2, and weight >40 kg; 5. Ethical compliance, patients voluntarily agree to participate in this trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Severe impairment of heart, lung, liver, and kidney function; 2.History of mental illness or long-term use of psychotropic medications (e.g., dementia, schizophrenia), chronic analgesic use, myasthenia gravis, or alcohol abuse; 3.Patients with severe infection; 4.Patients with language, hearing impairments, or brain dysfunction (e.g., stroke) that prevent communication; 5.Preoperative PaO2<60 mmHg or SpO2<92%; 6.Participation in another drug clinical trial within the past 30 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pulmonary complication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| postoperative muscle relaxation recovery effect;Hemodynamic indicators;Quality of recovery on the first postoperative day (Q-15 score scale);incidence of postoperative adverse events ;30-day postoperative readmission rate;length of hospital stay; | — |
Countries
China
Contacts
Public ContactDuan Jinjuan
Anqing Municipal Hospital
Outcome results
None listed